IDH1 and glioblastoma: Representing the older population of primary glioblastoma, we selected 174 IDH1-R132H1 immunonegative tumors from patients aged ≥ 60 years enrolled in the Nordic phase III trial in elderly patients with newly diagnosed glioblastomas, comparing standard RT, hypofractionated RT and temozolomide (TMZ) [14].